1. Home
  2. BMRC vs BWAY Comparison

BMRC vs BWAY Comparison

Compare BMRC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bank of Marin Bancorp

BMRC

Bank of Marin Bancorp

N/A

Current Price

$27.59

Market Cap

414.4M

Sector

Finance

ML Signal

N/A

Logo BrainsWay Ltd.

BWAY

BrainsWay Ltd.

N/A

Current Price

$16.15

Market Cap

337.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BMRC
BWAY
Founded
1989
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
414.4M
337.9M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BMRC
BWAY
Price
$27.59
$16.15
Analyst Decision
Buy
Strong Buy
Analyst Count
4
2
Target Price
$28.00
$23.50
AVG Volume (30 Days)
93.0K
61.3K
Earning Date
01-26-2026
11-11-2025
Dividend Yield
3.60%
N/A
EPS Growth
N/A
213.09
EPS
0.62
0.13
Revenue
$96,957,000.00
$49,094,000.00
Revenue This Year
$63.10
$330.76
Revenue Next Year
$15.24
$22.24
P/E Ratio
$44.99
$53.28
Revenue Growth
63.31
27.08
52 Week Low
$19.14
$7.84
52 Week High
$28.48
$18.18

Technical Indicators

Market Signals
Indicator
BMRC
BWAY
Relative Strength Index (RSI) 60.78 46.21
Support Level $26.52 $16.75
Resistance Level $28.21 $17.38
Average True Range (ATR) 0.65 0.75
MACD 0.03 -0.07
Stochastic Oscillator 54.08 21.06

Price Performance

Historical Comparison
BMRC
BWAY

About BMRC Bank of Marin Bancorp

Bank of Marin Bancorp is a United States-based bank holding company. It conducts business through its wholly-owned subsidiary. The Bank provides a wide range of financial services to customers such as professionals, small and middle-market businesses, and individuals residing in Marin, Sonoma, Napa, San Francisco, Alameda, Contra Costa, San Mateo counties and others. The majority of its revenue comes from interest income.

About BWAY BrainsWay Ltd.

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Share on Social Networks: